palovarotene
Selected indexed studies
- Palovarotene: First Approval. (Drugs, 2022) [PMID:35384641]
- Palovarotene. (Am J Health Syst Pharm, 2023) [PMID:37796111]
- Palovarotene in fibrodysplasia ossificans progressiva: review and perspective. (Expert Opin Pharmacother, 2025) [PMID:39834193]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Palovarotene: First Approval. (2022) pubmed
- Palovarotene. (2023) pubmed
- Palovarotene in fibrodysplasia ossificans progressiva: review and perspective. (2025) pubmed
- PMID:37934835 (2023) pubmed
- PMID:37643264 (2023) pubmed
- Palovarotene (Sohonos), a synthetic retinoid for reducing new heterotopic ossification in fibrodysplasia ossificans progressiva: history, present, and future. (2025) pubmed
- Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification. (2022) pubmed
- Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial. (2022) pubmed
- Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations. (2023) pubmed
- Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema. (2009) pubmed